Key Market Indicators
Sales of Slovak antirheumatic medicines is projected to reach $51.34 million by 2026. This represents a 1.8% average year-on-year growth, up from $46.53 million in 2021. Since 2001, the Slovak market has seen an average 4.3% year-on-year growth. Slovakia placed 15th in the 2021 rankings, falling behind Finland, which recorded sales of $46.53 million. Germany, Spain and Canada came in at numbers two, three and four respectively.
